3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
Gastrointestinal
2
Sarcoma
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Lymphoma
11
Lymphoma, Non-Hodgkin
10
Multiple Myeloma
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Hodgkin Disease
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
5
Hematologic Neoplasms
5
Burkitt Lymphoma
5
Neuroblastoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, B-Cell, Marginal Zone
4
Lymphoma, B-Cell
4
Leukemia, Myeloid, Acute
4
Breast Neoplasms
4
Neoplasm Metastasis
3
Myelodysplastic Syndromes
3
Melanoma
3
Lymphoma, T-Cell, Cutaneous
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Waldenstrom Macroglobulinemia
2
Sarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Lymphoma, T-Cell
2
Interventions
pembrolizumab
3
talimogene laherparepvec
2
spartalizumab
1
fludarabine
1
atezolizumab
1
aldesleukin
1
TTI-621
1
Radiation
1
RXDX-106
1
Proton Pump Inhibitors
1
Nivolumab
1
Ipilimumab
1
Interleukin-2
1
Injections, Subcutaneous
1
In Situ Hybridization, Fluorescence
1
Hydrocortisone
1
Gemcitabine
1
Cyclophosphamide
1
Carboxylesterase
1
Antineoplastic Protocols
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
Ipilimumab
×
Lymphoid
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts